Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001193125-22-091836
Filing Date
2022-03-31
Accepted
2022-03-31 16:23:49
Documents
5
Effectiveness Date
2022-03-31

Document Format Files

Seq Description Document Type Size
1 S-8 d333714ds8.htm S-8 44188
2 EX-5.1 d333714dex51.htm EX-5.1 5943
3 EX-23.2 d333714dex232.htm EX-23.2 1405
4 EX-FILING FEES d333714dexfilingfees.htm EX-FILING FEES 16534
5 GRAPHIC g333714g36m36.jpg GRAPHIC 9971
  Complete submission text file 0001193125-22-091836.txt   82991
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

EIN.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-264025 | Film No.: 22792915
SIC: 2836 Biological Products, (No Diagnostic Substances)